Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 8-K (Current Report)
Date of Report: June 3, 2024
Principal Event: Entry into a definitive Credit and Guaranty Agreement and repurchase of outstanding convertible notes.
Key Financial Metrics and Transaction Details
- New Debt Facility: Senior secured term loan facility of up to $92.1 million.
- Initial Funding: $67.1 million Initial Term Loan fully funded on June 3, 2024.
- Delayed Draw: $25.0 million available on or prior to June 3, 2025, contingent on FDA approval of narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
- Debt Repurchase: Repurchased $118.1 million aggregate principal of 5.25% Convertible Senior Notes due 2026 (55% of outstanding notes).
- Repurchase Price: Blended price of 74.75% of par value.
- Debt Extinguishment: Approximately $51 million in total debt extinguishment recognized.
- Remaining Debt: $97.9 million aggregate principal of 2026 Notes remains outstanding.
- Interest Rate: Adjusted term SOFR (3.00% floor) + 8.75% per annum; option to pay up to 50% of interest in kind (PIK) at SOFR + 10.25%.
- Maturity: June 3, 2028.
- Liquidity Covenant: Must maintain at least $25.0 million in unrestricted cash and cash equivalents.
Material Changes Versus Prior Period
This filing represents a significant restructuring of the Company's capital structure rather than a standard periodic financial update. Key changes include:
- Capital Structure Shift: Transition from a portion of convertible debt to senior secured term loans.
- Debt Reduction: Immediate reduction of $118.1 million in convertible note principal, resulting in a $51 million gain on extinguishment.
- Collateralization: New indebtedness is secured by a first-priority lien on substantially all tangible and intangible property, excluding royalty interests in OMIDRIA.
- Non-Dilutive: The transaction does not include equity consideration for lenders, preserving shareholder value.
Guidance, Outlook, Risks, and Contingencies
- Use of Proceeds: Initial loan proceeds were used to repurchase notes; delayed draw proceeds must fund narsoplimab commercialization and transaction costs.
- Future Repurchases: The Company may exchange up to $16.9 million of remaining 2026 Notes for cash and additional term loans or repurchase notes in open market transactions subject to cash limits.
- Mandatory Prepayments: Required from 60% of net cash proceeds from asset sales (100% if involving narsoplimab while delayed draw is outstanding), insurance recoveries, and 25% of OMIDRIA milestone payments.
- Prepayment Penalties: Make-whole premium plus 5.00% in Year 1; 5.00% in Year 2; 3.00% in Year 3.
- Regulatory Contingency: The $25.0 million delayed draw is contingent on FDA approval of narsoplimab.
- Forward-Looking Risks: Actual results may differ due to regulatory processes, market factors, and the ability to meet cash covenants.
Important Facts for Investor Verification
- Verify the current status of the FDA application for narsoplimab to assess the likelihood of drawing the $25.0 million delayed term loan.
- Confirm the Company's ability to maintain the $25.0 million unrestricted cash covenant given the new debt service obligations.
- Review the specific terms of the "make-whole" prepayment premium to understand the cost of early debt retirement.
- Monitor future repurchase activity of the remaining $97.9 million in 2026 Notes and its impact on the Company's liquidity.
- Assess the impact of the new senior secured lien on the Company's ability to secure future financing.